Population pharmacokinetics of cisplatin in Asian Indian cancer patients cisplatin in Indian cancer population Harish K. Kaushik et al.

Clinical Research and Regulatory Affairs

Volumn 26, Issue 4, 2009, Pages 84-92

  Kaushik, Harish K ^a   Kumar, Vijay S ^a   Kumar, Satish B ^a   Reddy, Narsimha Y ^a   Raghavaiah, V K ^b   Devarakonda, Krishna R ^c  

^a KAKATIYA UNIVERSITY   (India)

^b Department of Oncology   (India)

^c MEDTRONIC INC   (United States)

Author keywords

Cisplatin; Indian cancer patients; Population pharmacokinetics

Indexed keywords

CISPLATIN; CREATININE;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; FEMALE; HUMAN; INDIAN; KIDNEY FUNCTION; LABORATORY TEST; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; NEOPLASM; PHARMACOLOGICAL PARAMETERS; SEX DIFFERENCE; SMOKING; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 70449586972     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601330903252206     Document Type: Article

References (19)

1. Einhorn LH, Williams SD. The role of cisplatin in solid tumor therapy. N Engl J Med 1979;300:289-291.
2. Livingston RB. Cisplatin in the treatment of solid tumors: effect of dose and schedule. J Natl Cancer Inst 1989;81:724-725.
3. Fillastre JP, Raguenz-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett 1989;46:163-175.
4. Krakoff IH. Nephrotoxicity of cis-dichlorodiammine platinum (II). Cancer Treat Rep 1979;63:1523-1525.
5. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5:445-479.
6. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983;11:303-319.
7. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet 1986;11:387-401.
8. Beal SL, Boeckmann AJ, Scheiner LB (eds). NONMEM users guide.San Francisco:NONMEM Project Group, University of California, San Francisco;1992.
9. Kaushik HK, Kumar VS, Kumar SB, Reddy NY, Devarakonda KR. A simple and sensitive HPLC method for the detection of unchanged cisplatin in human plasma. Personal communication.
10. Ma J, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 1996;38:391-394.
11. Jongh F, Gallo J, Shen M, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004:54:105-112.
12. Hanada K, Nishijima K, Ogata H. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jap J Clin Oncol 2001;31:179-184.
13. Lopez-Flores G, Jurado R, Garcia-Lopez P. A high- performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples. J Pharmacol Toxicol Meth 2005:52:366-372.
14. El-khateeb M, Appleton TG, Charles BG, Gahan LR. Development of HPLC conditions for valid determination of hydrolysis products of cisplatin. J Pharm Sci 1999:88:319-326.
15. Nagai N, Ogata H. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 1998;38:1025-1034.
16. Andrews PA, Wung WE, Howell SB. A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem 1984;15:46-56.
17. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004;57:756-763.
18. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 1991;32:669-670.
19. Population PK Information FDA Population PK Guidance. Guidance for Industry: Population Pharmacokinetics, U.S. Department of Health and Human Services, Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 1999; CP 1.